Ming Z, Parent R, Lavallée M
Department of Physiology, Faculty of Medicine, Université de Montréal, Québec, Canada.
Circulation. 1997 Mar 18;95(6):1568-76. doi: 10.1161/01.cir.95.6.1568.
We considered that beta 2-adrenergic stimulation may dilate resistance coronary vessels by opening ATP-sensitive potassium (KATP) channels, thereby triggering NO formation.
In conscious instrumented dogs after beta 1-adrenergic blockade, intracoronary (IC) injections of acetylcholine (ACh), nitroglycerin (NTG), and pirbuterol (PIR), a selective beta 2-adrenergic agonist, were performed before and after blockade of NO formation with IC N omega-nitro-L-arginine methyl ester (L-NAME, 50 micrograms.kg-1.min-1 x 12 minutes) or blockade of KATP channels with IC glibenclamide (25 micrograms.kg-1.min-1 x 12 minutes followed by 2 micrograms.kg-1.min-1). PIR (50.0 ng/kg) increased coronary blood flow (CBF) by 32 +/- 6 from 43 +/- 7 mL/min and by only 11 +/- 2 (P < .01) from 40 +/- 7 mL/min after L-NAME. Increases in CBF to ACh were also reduced by L-NAME, but NTG responses were not. Before glibenclamide, PIR increased CBF by 33 +/- 5 from 45 +/- 7 mL/min and by only 14 +/- 3 (P < .01) from 36 +/- 5 mL/min thereafter. CBF responses to ACh and NTG were maintained after glibenclamide. Lemakalim, a selective opener of KATP channels, caused dose-dependent increases in CBF that were partially inhibited by L-NAME. In experiments in which CBF was controlled, the fall in distal coronary pressure caused by PIR was less after L-NAME or glibenclamide than before.
beta 2-Adrenergic dilation of resistance coronary vessels involves both the opening of KATP channels and NO formation. L-NAME antagonized lemakalim responses consistent with a link between the opening of KATP channels and NO formation in canine resistance coronary vessels.
我们认为β2 - 肾上腺素能刺激可能通过开放ATP敏感性钾(KATP)通道使阻力性冠状动脉血管扩张,从而引发一氧化氮(NO)的形成。
在对有意识的、已安装仪器的犬进行β1 - 肾上腺素能阻滞之后,在用冠状动脉内(IC)注射Nω - 硝基 - L - 精氨酸甲酯(L - NAME,50微克·千克⁻¹·分钟⁻¹×12分钟)阻断NO形成之前和之后,以及在用IC格列本脲(25微克·千克⁻¹·分钟⁻¹×12分钟,随后为2微克·千克⁻¹·分钟⁻¹)阻断KATP通道之前和之后,分别进行冠状动脉内注射乙酰胆碱(ACh)、硝酸甘油(NTG)和选择性β2 - 肾上腺素能激动剂吡布特罗(PIR)。PIR(50.0纳克/千克)使冠状动脉血流量(CBF)从43±7毫升/分钟增加32±6,而在L - NAME之后,从40±7毫升/分钟仅增加11±2(P <.01)。L - NAME也降低了对ACh的CBF增加,但对NTG的反应未受影响。在格列本脲之前,PIR使CBF从45±7毫升/分钟增加33±5,之后从36±5毫升/分钟仅增加14±3(P <.01)。格列本脲之后,对ACh和NTG的CBF反应得以维持。KATP通道的选择性开放剂雷马卡林引起CBF剂量依赖性增加,且部分被L - NAME抑制。在控制CBF的实验中,L - NAME或格列本脲之后,PIR引起的冠状动脉远端压力下降比之前更小。
阻力性冠状动脉血管的β2 - 肾上腺素能扩张涉及KATP通道的开放和NO的形成。L - NAME拮抗雷马卡林反应,这与犬阻力性冠状动脉血管中KATP通道开放和NO形成之间的联系一致。